PAR 5.00% 19.0¢ paradigm biopharmaceuticals limited..

Ann: iPPS SIGNIFICANT OA PAIN REDUCTION AT 12 MONTHS, page-38

  1. 214 Posts.
    lightbulb Created with Sketch. 104
    so does this mean that given that the Para 002 study has not included the twice weekly dosage in its design that we are effectively starting again on the phase 3 study? It seems that it might mean that to me.
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.